Clinical Research Directory

Inclusion Criteria: * Histologically or cytologically confirmed biochemically recurrent prostate cancer, with original diagnosis no more than 2 years from date of consent. * Intermediate unfavorable or high-risk prostate cancer. * All patients under consideration for radiation therapy, either at the time of first recurrence or in salvage radiation therapy will be included. * Patients who have started bicalutamide up to a maximum of 3 days prior to randomization will be allowed to be on protocol. Otherwise, a washout period of at least 42 days will be required. * Biological males, at least 18 years of age. * Prostate specific antigen (PSA) \< 1.0 ng/mL. * Agreement to adhere to Lifestyle Considerations throughout study duration * Ability to understand and willingness to sign an IRB approved written informed consent document. Exclusion Criteria: * Patients currently on androgen deprivation therapy (ADTs). * Currently receiving any other investigational agents. * A history of allergic reactions attributed to compounds of similar chemical or biologic composition to POSLUMA, furosemide, bicalutamide, or other agents used in the study.